healthpharma
Biodexa Pharmaceuticals PLC (NASDAQ: BDRX) opened more than 100% up on Tuesday after reporting encouraging Phase 2 data for eRapa. Details of the Phase 2 data reported todayThe recently licensed drug for FAP (familial adenomatous polyposis) showed non-progression rate of 83% and lowered total polyp burden by about 24% versus the baseline upon six months of treatment. $BDRX reported two grade 3 adverse events while the remaining 97% of the participants remained on eRapa after six months. All in all, the Phase 2 data established eRapa as “safe and well-tolerated” on Tuesday. The news arrives abo...
Invezz
Sanofi SA (EPA: SAN) is in focus today after teaming up with OpenAI to deploy artificial intelligence for drug development. What’s in it for Sanofi?Working with the AI company will help Sanofi “go to market faster with our drugs” and address the unmet patient needs, as per Emmanuel Frenehard – executive vice president of the pharmaceutical behemoth. The OpenAI partnership may also $SAN in terms of improving its operating profit. The French multinational is committed to capitalising on artificial intelligence to “shorten the process from discovery all the way to development” of a drug, its exec...
Invezz
Eli Lilly and Company announced on Tuesday that the National Medical Products Administration (NMPA) in China has approved the distribution of its injection Mufenda. This injection is designed to treat diabetes, improve blood sugar control, and aid in weight loss for adults with type 2 diabetes. The approval marks a significant milestone for Eli Lilly as it aims to expand its footprint in the giant Asian market. Addressing China’s diabetes challengeChina faces a significant challenge with diabetes, with a large portion of its population affected by the condition. The Healthy China 2030 plan out...
Invezz
Hims & Hers Health (NYSE: HIMS) stock price is doing well, helped by its strong growth and demand for its core products. It soared by over 30% this year and by more than 112% this year. It has also surged by over 37% in the past 12 months, giving it a market cap of $3.13 billion. Growth is gaining momentumHims & Hers Health’s business is doing well. Data released this month revealed that its total revenue soared by 46% in Q1 to over $278 million as its subscribers roared by 41% to 1.7 million. This performance makes it one of the fastest growing companies in the US. The company’s gross margin ...
Invezz
GT Biopharma Inc (NASDAQ: GTBP) is up a whopping 150% at writing even though there hasn’t been any news to catalyse that sort of a rally in shares of the clinical-stage biopharmaceutical company. GT Biopharma stock trading volume today$GTBP did not publish a press release or file with the Securities & Exchange Commission on Monday. None of the Wall Street analysts issued a bullish note on it either. Still, more than 20 million shares of the Nasdaq-listed firm have exchanged hands today as of writing. The daily trading volume is up massively from about 10,000 only on average. The massive rally ...
Invezz
Healwell AI (TSX: AIDX) has had an impressive turnaround, making it one of the best-performing Canadian technology companies this year. Its stock is already up by over 100% in 2024, helped by its investments in Artificial Intelligence (AI), its partnership with Well Health Technologies, and its improving balance sheet. It has jumped by ~620% in the past 12 months, beating popular AI names like Nvidia (NVDA) and SoundHound AI (SOUN). Turnaround continuesHealwell AI, formerly known as MCI OneHealth, has implemented a strong turnaround that has saved the company from bankruptcy. Before this turna...
Invezz
Akanda Corp (NASDAQ: AKAN) is in focus this morning after receiving a notice of non-compliance from Nasdaq. Akanda fails to satisfy the Nasdaq listing requirementsThe deficiency notification was issued to the international medical cannabis company because it failed to meet the “minimum stockholders’ equity requirement as set forth in Nasdaq Listing Rule 5550(b)(1). $AKAN failed to satisfy the alternative compliance standards “based on market value of listed securities or net income from continuing operations” as well, a press release confirmed on Friday. Note that Akanda stock saw a massive de...
Invezz
Walgreens Boots Alliance Inc (NASDAQ: WBA) is gaining at writing following a report that it’s contacting buyers who may be interested in taking over Boots. What is Boots UK worth?The drugstore chain based out of Nottingham, United Kingdom is worth close to $9.0 billion. Walgreens has already engaged with advisors to hold preliminary talks with the potential buyers, as per sources that talked to Bloomberg on condition of anonymity. What the Nasdaq-listed firm plans on doing with proceeds provided that it does indeed secure a deal remains unclear. Lowering the debt on its balance sheet, however,...
Invezz
iTeos Therapeutics Inc (NASDAQ: ITOS) is up 30% today after announcing plans of a registered direct offering. iTeos Therapeutics stock pops on Q1 earningsThe biotechnology company will sell a total of 1,142,857 shares at $17.50 each which translates to a 44% premium on its previous close. The offering will also include “pre-funded warrants to purchase up to 5,714,285 shares”, as per its press release on Friday. Also today, $ITOS said it lost $38.2 million or $1.07 per share in Q1. That came in up significantly from a $15.6 million loss or 44 cents per share in the same quarter last year. Still...
Invezz
Novavax (NASDAQ:NVAX) shares rocketed 40% in premarket trading Friday, driven not only by the company’s fiscal Q1 2024 earnings report but more significantly, by a crucial multi-billion dollar deal with French pharmaceutical giant Sanofi SA. Despite reporting a first-quarter loss per share of $1.05, wider than the $0.92 anticipated by analysts, and revenue of $93.85 million which fell short of the consensus estimate of $141.16 million, the announcement of the partnership spurred a dramatic increase in Novavax’s stock value. Novavax’s deal with Sanofi boosts investor confidenceThe licensing agr...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら